Lisbon's Champalimaud Foundation Leads Global Cancer-Brain Research With €21.4M Project

A Portugal-based Fundação Champalimaud has secured its place in a groundbreaking international study exploring whether the human brain can detect cancer growing inside the body — and whether it inadvertently helps or hinders tumor development. The Lisbon research center will receive a share of up to $25M (€21.4M) over the next five years, positioning Portugal at the forefront of a field that could redefine how oncology treats the disease.

Why This Matters

• Major funding: The InteroCANCEption consortium — one of just five winners globally — begins work on May 1, 2026, with backing from the Cancer Research UK and the U.S. National Cancer Institute.

• Portugal's role: The Champalimaud Foundation will focus specifically on pancreatic, lung, and colorectal cancers, examining how neural pathways interact with these tumor types.

• New treatment frontier: If successful, the research could lead to therapies that manipulate brain signals to suppress cancer growth or manage debilitating symptoms like pain and weight loss.

• Public symposium: Champalimaud will host the "Neural and Immune Codes in Cancer" symposium from October 14–16, 2026, bringing global experts to Lisbon.

The Core Question: Does Your Brain Know You Have Cancer?

Led by London's Francis Crick Institute, the InteroCANCEption project asks two deceptively simple questions that have never been systematically answered: Can the brain sense a tumor forming somewhere in the body? And if so, does the neurological response help fight the malignancy — or accidentally fuel it?

Henrique Veiga-Fernandes, the Portugal-based principal investigator from Champalimaud, frames the challenge as uncovering "hidden communication" between cerebral circuits and malignant tissue. "There is clear evidence that nerves can both promote and suppress tumor growth," he explained. "What we lack is an understanding of the rules and principles governing these interactions."

The consortium spans eight institutions across four countries — Portugal, Switzerland, the United Kingdom, and the United States — and includes clinicians, neuroscientists, immunologists, and patient advocates. It's this last group that Veiga-Fernandes highlights as particularly transformative: patient representatives participated directly in the finalist selection interviews, a model he describes as "a powerful way to make the scientific process more open and integrate the perspectives of those who may ultimately benefit."

From Cellular Disease to Systemic Disorder

Traditional oncology has treated cancer as a localized rebellion of cells and tissues. But mounting evidence shows that tumors do not exist in isolation. Nerves infiltrate many cancer types, influencing not just tumor proliferation but also immune system behavior and patient symptoms such as chronic pain and cachexia (severe weight loss).

Recent studies — including work from Brazilian universities such as the Federal University of Minas Gerais and the University of São Paulo — have shown that sensory nerves can suppress melanoma growth by reducing blood vessel formation and increasing cancer cell death. Conversely, sympathetic and parasympathetic nerves have been linked to metastasis facilitation in breast, prostate, and colon cancers, with higher nerve density around tumors often predicting worse outcomes.

This dual role — nerves as both tumor suppressors and promoters — is what makes the InteroCANCEption project so urgent. The research will map neural pathways, track brain activity, and identify which signals correlate with cancer progression. The ultimate goal: to determine whether modulating neural activity can alter how cancer behaves.

What This Means for Residents and Expats in Portugal

For those living in Portugal, this development carries both immediate and long-term implications. The Champalimaud Foundation, already one of Europe's premier biomedical research centers, will become a hub for cutting-edge neuro-oncology over the next half-decade. This positions Lisbon as a magnet for international talent and collaboration — and potentially as an early-access site for experimental therapies emerging from the project.

Patients in Portugal diagnosed with pancreatic, lung, or bowel cancers may eventually have the opportunity to participate in clinical trials exploring neural modulation as an adjunct to standard treatment. While such trials are years away, the research could yield faster breakthroughs in symptom management — for instance, using existing neurological or psychiatric drugs to mitigate cancer-related pain or appetite loss.

The October symposium will also draw a global audience to Lisbon, reinforcing Portugal's reputation as a serious player in life sciences research. For expats and locals working in biotech, pharmaceuticals, or academic research, the influx of expertise and capital represents a meaningful career development ecosystem.

The Ambition: Reprogramming the Brain to Fight Tumors

María Martínez López, a postdoctoral researcher in Veiga-Fernandes' laboratory, outlined the project's most audacious aim: "If we can understand the circuits linking the brain to tumors, we may be able to design entirely new types of therapies." That could mean anything from repurposing existing drugs that affect neural activity to deploying neural implants or transcranial magnetic stimulation to alter how the brain signals tumors.

One promising avenue involves interoception — the brain's ability to sense and regulate the body's internal state via the nervous system. The InteroCANCEption team will investigate whether the brain can detect biochemical or structural changes associated with early tumor formation, and whether enhancing or dampening that interoceptive signal might influence cancer outcomes.

Animal studies have already shown that superactivating sensory neurons can shrink tumors and improve anti-tumor immune responses. The challenge now is translating those findings to human patients and determining which neural pathways are safe and effective to manipulate.

Five Global Moonshots, One Initiative

The InteroCANCEption consortium is one of five teams selected in the latest Cancer Grand Challenges round, announced on March 4, 2026. The initiative — jointly funded by the U.S. National Cancer Institute and Cancer Research UK — has now allocated $624M since 2016 to tackle the most stubborn and underexplored questions in oncology.

The other four winning projects include:

• Team ATLAS (led by Institut Imagine, Paris): Studying people who never develop cancer despite risk factors, hunting for protective auto-antibodies.

• Team REWIRE-CAN (UCL Cancer Institute, London): Attempting to "rewire" cancer cells to self-destruct rather than merely blocking their growth.

• Team ILLUMINE (Netherlands Cancer Institute): Decoding the "dark proteome" — proteins whose functions are unknown but may drive malignancy.

• Team CAUSE (University of California San Diego): Developing new chemistry to uncover unknown causes of DNA damage that trigger cancer.

Each team receives up to $25M over approximately five years, with the expectation that breakthrough findings will be shared openly across the global research community.

Practical Timelines and Next Steps

InteroCANCEption officially launches on May 1, 2026. Over the subsequent 60 months, the consortium will:

• Map neural circuits in pancreatic, lung, and colorectal tumors.

• Use brain imaging to identify activity patterns associated with tumor detection.

• Test whether drugs, implants, or other neuromodulation techniques can influence tumor behavior or symptom burden.

• Publish findings in open-access journals and present at international conferences, including the Champalimaud Research Symposium in October.

For clinicians and patients in Portugal, the most immediate opportunity is engagement with the October symposium, which is expected to draw interdisciplinary researchers from oncology, neuroscience, and immunology. Registration details will be announced by the Champalimaud Foundation in the coming months.

A Paradigm Shift in Cancer Biology

The InteroCANCEption project represents a paradigm shift from viewing cancer as a rogue tissue to understanding it as a systemic disorder embedded in the body's complex physiology. Tumors communicate with the nervous system, the immune system, and potentially the brain itself. Unraveling that crosstalk could unlock therapies that don't just target cancer cells, but instead harness the body's own regulatory networks to suppress malignancy or ease suffering.

For Portugal, the inclusion of the Champalimaud Foundation in this elite consortium is both a validation of its scientific infrastructure and a signal that Lisbon is becoming a node in global health innovation. The next five years will determine whether the brain truly "knows" when cancer strikes — and whether neuroscience can teach oncology an entirely new language.